Literature DB >> 20063025

Infections by pandrug-resistant gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients.

C Tsioutis1, E I Kritsotakis, S Maraki, A Gikas.   

Abstract

Clinical reports on infections by pandrug-resistant (PDR) bacteria are scarce. This observational case series study was conducted during a 2-year period at a university hospital. Patients infected by PDR gram-negative bacteria comprised the study cohort. An isolate was defined as PDR if it was resistant to all antibiotic classes available for empirical treatment. A total of 21 patients infected by PDR gram-negative bacteria were recorded. The mean APACHE II score on admission was 18.8, the mean Charlson comorbidity index was 2.9, and 20 (95.2%) patients had a history of intensive care unit hospitalization. All patients had recent exposure to multiple antibiotics (median, 6 antibiotic groups). Infections occurred at a mean of 41.5 days after admission. The mean length of stay after infection was 54.6 days and 5 (23.8%) patients died due to the infection. Treatment was mainly based on a colistin-containing regimen (47.6%) or tigecycline (33.3%). All patients treated with tigecycline had total resolution of the infection and a notably shorter length of hospital stay after infection. In conclusion, PDR gram-negative bacterial infections are associated with considerable prolongation of hospitalization and mortality, although the mortality is not as high as that expected. Tigecycline appears to be effective for the successful treatment of PDR infections

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063025     DOI: 10.1007/s10096-009-0857-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin.

Authors:  P Beno; V Krcmery; A Demitrovicova
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

2.  EUCAST technical note on tigecycline.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2006-11       Impact factor: 8.067

3.  Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.

Authors:  Matthew E Falagas; Petros I Rafailidis; Dimitrios K Matthaiou; Simona Virtzili; Dimitra Nikita; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2008-09-02       Impact factor: 5.283

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

Authors:  Shiri Navon-Venezia; Azita Leavitt; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-03-12       Impact factor: 5.790

6.  Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.

Authors:  Anton Y Peleg; Brian A Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J Kwak; Sunil V Bhat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2006-11-01       Impact factor: 5.790

Review 7.  Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.

Authors:  Theodoros Kelesidis; Drosos E Karageorgopoulos; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-08-01       Impact factor: 5.790

8.  A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Authors:  Krasimir Vasilev; Galina Reshedko; Remus Orasan; Miguel Sanchez; Juri Teras; Tim Babinchak; Gary Dukart; Angel Cooper; Nathalie Dartois; Hassan Gandjini; Russ Orrico; Evelyn Ellis-Grosse
Journal:  J Antimicrob Chemother       Date:  2008-09       Impact factor: 5.790

Review 9.  Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.

Authors:  Azza Elemam; Joseph Rahimian; William Mandell
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.

Authors:  Matthew E Falagas; Ioannis A Bliziotis; Sofia K Kasiakou; George Samonis; Panayiota Athanassopoulou; Argyris Michalopoulos
Journal:  BMC Infect Dis       Date:  2005-04-08       Impact factor: 3.090

View more
  13 in total

Review 1.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

Review 2.  Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view.

Authors:  Mathias W Pletz; Nele Wellinghausen; Tobias Welte
Journal:  Intensive Care Med       Date:  2011-05-15       Impact factor: 17.440

3.  Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.

Authors:  G Samonis; E Koutsounaki; D E Karageorgopoulos; P Mitsikostas; C Kalpadaki; V Bozionelou; I Bompolaki; J Sgouros; V Taktikou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-31       Impact factor: 3.267

4.  Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria.

Authors:  Diamantis P Kofteridis; Angeliki M Andrianaki; Sofia Maraki; Anna Mathioudaki; Marina Plataki; Christina Alexopoulou; Petros Ioannou; George Samonis; Antonis Valachis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-13       Impact factor: 3.267

5.  Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Sue C Kehl; Michael J Dowzicky
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

6.  Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Hee Ji Lee; Phillip J Bergen; Jurgen B Bulitta; Brian Tsuji; Alan Forrest; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

7.  Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090.

Authors:  John D Williams; Son T Nguyen; Shen Gu; Xiaoyuan Ding; Michelle M Butler; Tommy F Tashjian; Timothy J Opperman; Rekha G Panchal; Sina Bavari; Norton P Peet; Donald T Moir; Terry L Bowlin
Journal:  Bioorg Med Chem       Date:  2013-10-25       Impact factor: 3.641

Review 8.  Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

Authors:  Phillip J Bergen; Cornelia B Landersdorfer; Jing Zhang; Miao Zhao; Hee Ji Lee; Roger L Nation; Jian Li
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-06       Impact factor: 2.803

Review 9.  Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review.

Authors:  Mandana Izadpanah; Hossein Khalili
Journal:  J Res Pharm Pract       Date:  2015 Jul-Sep

10.  Clinical treatment of pandrug-resistant bacterial infection consulted by clinical pharmacist.

Authors:  Yang Zhi-Wen; Zhang Yan-Li; Yuan Man; Fang Wei-Jun
Journal:  Saudi Pharm J       Date:  2015-01-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.